



Dr Norbert Pardi holds a Ph.D. in biochemistry and genetics. He has been working at the University of Pennsylvania since 2011. His research interest is the development of mRNA-based therapeutics with particular focus on new generation vaccines. He explored the development of a novel protein delivery platform using nucleoside-modified mRNA in lipid nanoparticles (LNPs) and used it to generate highly efficacious mRNA-LNP vaccines targeting various pathogens.